Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study
Abstract Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes the lungs of surfactant, leading to prolonged mechanical ventilation and death. The feasibility and safety of surfactant delivery in COVID-19 ARDS patients have not been established. Methods We performed retr...
Main Authors: | Simone Piva, Robert M. DiBlasi, April E. Slee, Alan H. Jobe, Aldo M. Roccaro, Matteo Filippini, Nicola Latronico, Michele Bertoni, John C. Marshall, Michael A. Portman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-020-01603-w |
Similar Items
-
Pulmonary Surfactant Preparations and Surfactant Therapy for ARDS in Surgical Intensive Care (a Literature Review)
by: O. A. Rosenberg
Published: (2019-04-01) -
Tracing exogenous surfactant in vivo in rabbits by the natural variation of 13C
by: Sonia Giambelluca, et al.
Published: (2019-07-01) -
Endotracheal Surfactant Combined With Budesonide for Neonatal ARDS
by: Burak Deliloglu, et al.
Published: (2020-05-01) -
Surfactant alteration and replacement in acute respiratory distress syndrome
by: Walmrath Dieter, et al.
Published: (2001-10-01) -
Early versus late extubation after surfactant replacement therapy for respiratory distress syndrome
by: Mohamed Garib, et al.
Published: (2015-03-01)